- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Brandon Blue, MD | Authors
Selecting First-Line Therapy for Patients With Transplant-Ineligible NDMM
January 25, 2023
Moving on to review the management of transplant-ineligible NDMM, expert panelists highlight first-line treatment options with data from the SWOG0777 and MAIA studies.
Patient Profile 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
January 25, 2023
Centering focus on a patient scenario of transplant-eligible newly diagnosed multiple myeloma, panelists consider the role of induction therapy and transplant in this setting.
Selection of Induction Therapy in Patients With Transplant-Eligible NDMM
January 20, 2023
Shared insight from experts in multiple myeloma on the real-world utilization of induction therapy and transplant for patients with newly diagnosed disease.
Transplant-Eligible NDMM: Overview of Available Induction Therapies
January 20, 2023
Experts from the Moffit Cancer Center share insight on induction therapy strategies and optimization for patients with transplant-eligible newly diagnosed multiple myeloma.